

Please type a plus (+) inside this box --



12-07-01

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 7853-251-999 Total Pages 325

First Named Inventor or Application Identifier

Douglas A. Levinson

Express Mail Label No. EL 477 032 915 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form
Submit an original, and a duplicate for fee processing
2. ☐ Applicant claims Small Entity status, see 37 C.F.R. § 1.27
3. ☒ Specification [Total Pages 220]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings *(if filed)*
 - Detailed Description of the Invention *(including drawings, if filed)*
 - Claim(s)
 - Abstract of the Disclosure
4. Drawing(s) (35 USC 113) [Total Sheets 47]
5. ☒ Oath or Declaration [Total Sheets 2]
 - ☐ Newly executed (original or copy)
 - ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 19 completed)
- i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. ☒ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☐ Computer Readable Copy
 - b. ☒ Paper Copy (identical to computer copy)
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
11. ☐ English Translation Document *(if applicable)*
12. ☒ Information Disclosure Statement ☐ Copies of IDS
(IDS)/PTO-1449 Citations
13. ☒ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(i).
Applicant must attach form PTO/SB/35 or its equivalent
17. ☐ Other:

18. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:
☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: 09/324,986 filed June 2, 1999.

19. CORRESPONDENCE ADDRESS

Customer Number:



20583

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

NAME

ADDRESS

CITY

STATE

ZIP CODE

COUNTRY

TELEPHONE

FAX

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEPrior application: Examiner R. SwartzArt Unit 1645

Assistant Commissioner for Patents
 Box PATENT APPLICATION
 Washington, D.C. 20231

Sir:

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR § 1.53(b), of pending prior application no. 09/324,986 filed on June 2, 1999.

of Douglas A. Levinson, Clare M. Lloyd, and Sean A. McCarthy
 (inventor(s) currently of record in prior application)

for COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS.
 (title of invention)

1. ☒ The filing fee is calculated below:

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	37	-20	17	\$18.00 each	\$ 306.00
Independent	3	-3	0	\$84.00 each	\$ 0.00
Basic Fee					\$ 740.00
Multiple Dependency Fee If Applicable (\$280.00)					\$ 280.00
Total					\$ 1,326.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern					- \$ 0.00
Total Filing Fee					\$ 1,326.00

2. ☒ Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.
3. ☐ Amend the specification by inserting before the first line the following sentence: This is a continuation of application no. filed
- 4a. ☐ New formal drawings are enclosed.

- 4b. ☒ Informal drawings are enclosed.
- 5a. ☐ Priority of application no. filed on in is claimed under 35 U.S.C. §119.
- 5b. ☐ The certified copy has been filed in prior application no. , filed .
6. ☒ The prior application is assigned of record to Millennium Pharmaceuticals, Inc. at Reel 010632, Frame 0418.
- 7a. ☒ A copy of the Power of Attorney filed in the prior application no. 09/324,986, filed June 2, 1999 is enclosed.
- 7b. ☐ A Power of Attorney is enclosed.
8. ☒ This application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior application no.09/324,986, filed on June 2, 1999 be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from application no. 09/324,986 is enclosed.
9. ☒ The undersigned states, under 37 C.F.R. §1.821(f), that the content of the enclosed paper Sequence Listing from application no. 09/324,986 is the same as the content of the computer readable form submitted in application no. 09/324,986.
10. ☐ DO NOT PUBLISH. I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).
11. ☒ Enclosed herewith are: (1) an Information Disclosure Statement; (2) a revised PTO-1449 form; and (3) a Preliminary Amendment with Exhibit A.

Respectfully submitted,

Date December 4, 2001

Laura A. Coruzzi 30,742
 Laura A. Coruzzi (Reg. No.)
 PENNIE & EDMONDS LLP
 1155 Avenue of Americas
 New York, N.Y. 10036-2711

By: Jennifer J. Chedea
 Reg No. 46,617

FOI0027 EE940001

Express Mail No. _____ First Class Mail ()
Date Mailed _____
Ser. No. _____
Inventor/M Date Mailed: December 4, 2001
For Serial No.: To be assigned
Filed: Herewith
Inventor(s): Levinson et al.
For: COMPOSITIONS AND METHODS FOR THE TREATMENT AND
DIAGNOSIS OF IMMUNE DISORDERS
The stamp of the Patent Office hereon shall be taken as an
acknowledgment of the date stamped of the following:
Utility Patent Application Transmittal Cover Sheet
Request for Continuation Application Under 37 C.F.R. § 1.53(b) (in
duplicate)
Copy of Application 220 pages
37 Claims 47 Drawing sheets
Copy of executed Declaration
Sequence Listing in paper format
Preliminary Amendment (with attached Exhibit A)
Information Disclosure Statement (in duplicate)
Revised PTO Form 1449
File No. 7853-251 Sender: LAC/NCG/JJC
File No. _____

EXPRESS MAIL NO. : EL 477 032 915 US

JC781 U.S. PTO
10/004633
12/04/01

BEST AVAILABLE COPY